AICAR vs CagriSema
A side-by-side research comparison of AICAR and CagriSema across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AICAR | CagriSema |
|---|---|---|
| Full name | AICAR (AMPK Activator / Exercise Mimetic) | CagriSema (Cagrilintide + Semaglutide) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | AICAR is converted intracellularly to ZMP, which mimics AMP and directly activates AMP-activated protein kinase (AMPK). AMPK activation shifts metabolism toward fat burning, mitochondrial biogenesis, and glucose uptake, mimicking effects of endurance exercise. | Dual-pathway activation: cagrilintide mimics amylin to activate area postrema satiety centers, while semaglutide activates GLP-1 receptors for complementary appetite suppression. |
| Molecular weight | 258.23 Da | Combination product |
| Half-life | Short | 7 days (both components) |
| Bioavailability | Injection (research); poor oral | High (SubQ) |
| Typical dose | Not established for humans | Cagrilintide 2.4mg + Semaglutide 2.4mg |
| Frequency | Research only | Once weekly |
| Route | Injection (research) | Subcutaneous |
AICAR reported benefits
- AMPK activation (exercise-mimetic)
- Increased fat oxidation
- Mitochondrial biogenesis
- Improved endurance (animal models)
- Enhanced glucose uptake
CagriSema reported benefits
- Enhanced weight loss vs monotherapy
- Dual appetite suppression
- Convenient single injection
- Improved metabolic parameters
- Potential 20-25% weight loss
Related comparisons
Research and educational reference only. Not medical advice.